Wire · operational-macro
U.S. Rare Disease Biotech Investing Rises After FDA's PRV Program Renewal: Report
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 August 2026 · Fusion42 review
Renewal of the FDA's Priority Review Voucher (PRV) program has increased investment in U.S. rare disease biotechs, providing financial certainty and tradable non-dilutive capital; the UK lags behind due to the lack of an equivalent incentive scheme despite regulatory improvements.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your rare disease biotech gains a funding lifeline through the FDA's PRV program renewal, making U.S. investment more attractive and liquidity clearer. UK founders face a widening capital gap without a similar voucher scheme, signalling a need to reposition or seek US partnerships.
◆ Coverage
2 sources · 11 Aug 2026
◆ Related on Wire
◆ Topics